• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Select a suitable treatment strategy for Crohn's disease: step-up or top-down.为克罗恩病选择合适的治疗策略:逐步升级还是自上而下。
EXCLI J. 2014 Feb 13;13:111-22. eCollection 2014.
2
[Anti-TNF therapy in treatment of luminal Crohn's disease].[抗TNF治疗在腔内型克罗恩病治疗中的应用]
Acta Med Croatica. 2013 Apr;67(2):179-89.
3
Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?克罗恩病的早期治疗:我们是否有足够的证据来颠覆治疗金字塔?
J Gastrointestin Liver Dis. 2012 Mar;21(1):67-73.
4
Top-down approach to biological therapy of Crohn's disease.克罗恩病生物治疗的自上而下方法。
Expert Opin Biol Ther. 2017 Mar;17(3):285-293. doi: 10.1080/14712598.2017.1287170. Epub 2017 Feb 6.
5
Practical Approaches to "Top-Down" Therapies for Crohn's Disease.克罗恩病“自上而下”疗法的实用方法
Curr Gastroenterol Rep. 2016 Jul;18(7):35. doi: 10.1007/s11894-016-0507-z.
6
Preventing Collateral Damage in Crohn's Disease: The Lémann Index.预防克罗恩病中的附带损害:莱曼指数。
J Crohns Colitis. 2016 Apr;10(4):495-500. doi: 10.1093/ecco-jcc/jjv240. Epub 2016 Jan 7.
7
What is the optimal therapy for Crohn's disease: step-up or top-down?对于克罗恩病,最佳的治疗方法是什么:逐步升级还是自上而下?
Expert Rev Gastroenterol Hepatol. 2010 Apr;4(2):167-80. doi: 10.1586/egh.10.4.
8
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change.早期使用免疫抑制剂或 TNF 拮抗剂治疗克罗恩病:是时候改变了。
Gut. 2011 Dec;60(12):1754-63. doi: 10.1136/gutjnl-2011-300934. Epub 2011 Oct 13.
9
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.生物治疗对克罗恩病的应答随着早期治疗而改善:对健康索赔数据的分析。
Inflamm Bowel Dis. 2012 Dec;18(12):2225-31. doi: 10.1002/ibd.22925. Epub 2012 Feb 22.
10
Current therapeutic approaches in inflammatory bowel disease.炎症性肠病的当前治疗方法。
Curr Pharm Des. 2010;16(33):3668-83. doi: 10.2174/138161210794079155.

引用本文的文献

1
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.在 E5 欧洲五国(E5)中,采用皮下注射英夫利昔单抗(CT-P13 SC)治疗炎症性肠病的预算影响分析。
BMC Health Serv Res. 2022 Nov 4;22(1):1319. doi: 10.1186/s12913-022-08683-y.
2
Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis.免疫调节剂使用对溃疡性结肠炎患者治疗持续性的影响:一项基于索赔数据库的分析。
J Gastroenterol Hepatol. 2020 Feb;35(2):225-232. doi: 10.1111/jgh.14825. Epub 2019 Sep 3.
3
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.亚洲溃疡性结肠炎和克罗恩病免疫调节剂及生物制剂的最佳实践
Intest Res. 2019 Jul;17(3):285-310. doi: 10.5217/ir.2019.00026. Epub 2019 May 31.
4
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.成人炎症性肠病的药物治疗和非药物治疗方法
World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):5-20. doi: 10.4292/wjgpt.v7.i1.5.

本文引用的文献

1
Exclusive enteral nutrition and induction of remission of active Crohn's disease in children.肠内营养专食与儿童活动期克罗恩病的诱导缓解。
Expert Rev Clin Immunol. 2013 Apr;9(4):375-83; quiz 384. doi: 10.1586/eci.13.12.
2
Vaccination strategies in patients with IBD.炎症性肠病患者的疫苗接种策略。
Nat Rev Gastroenterol Hepatol. 2013 May;10(5):277-85. doi: 10.1038/nrgastro.2013.28. Epub 2013 Feb 19.
3
Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.老年发病炎症性肠病的自然史:一项基于人群的队列研究。
Gut. 2014 Mar;63(3):423-32. doi: 10.1136/gutjnl-2012-303864. Epub 2013 Feb 13.
4
Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort.当前吸烟仍是炎症性肠病的一个重要环境因素吗?基于人群的发病队列研究结果。
Inflamm Bowel Dis. 2013 Apr;19(5):1010-7. doi: 10.1097/MIB.0b013e3182802b3e.
5
Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.遗传易感性增加细菌易位会影响克罗恩病患者对生物治疗的反应。
Gut. 2014 Feb;63(2):272-80. doi: 10.1136/gutjnl-2012-303557. Epub 2013 Feb 1.
6
Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.基因多态性可预测银屑病及相关自身免疫性疾病患者对抗 TNF 治疗的反应。
Pharmacogenomics J. 2013 Aug;13(4):297-305. doi: 10.1038/tpj.2012.53. Epub 2013 Jan 22.
7
Geographical variability and environmental risk factors in inflammatory bowel disease.炎症性肠病的地域变异性和环境风险因素。
Gut. 2013 Apr;62(4):630-49. doi: 10.1136/gutjnl-2012-303661. Epub 2013 Jan 18.
8
Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine.间充质干细胞:造血干细胞龛的基石和再生医学的踏脚石。
Annu Rev Immunol. 2013;31:285-316. doi: 10.1146/annurev-immunol-032712-095919. Epub 2013 Jan 3.
9
The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine.意义、概念和重要性:将间充质干细胞科学转化为医学。
Nat Med. 2013 Jan;19(1):35-42. doi: 10.1038/nm.3028. Epub 2013 Jan 7.
10
NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people.NICE 临床指南(CG152):成人、儿童和青少年克罗恩病的管理。
Aliment Pharmacol Ther. 2013 Jan;37(2):195-203. doi: 10.1111/apt.12102. Epub 2012 Nov 14.

为克罗恩病选择合适的治疗策略:逐步升级还是自上而下。

Select a suitable treatment strategy for Crohn's disease: step-up or top-down.

作者信息

Chen Qian-Qian, Yan Li, Wan Jun

机构信息

Department of Nanlou Gastroenterology, Chinese PLA General Hospital, Beijing, China.

出版信息

EXCLI J. 2014 Feb 13;13:111-22. eCollection 2014.

PMID:26417246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4463423/
Abstract

Crohn's Disease (CD) is a chronic immune-mediated disorder with progressive and destructive course. Current guidelines on the treatment strategy still recommend a step-up approach with sequential prescription of corticosteroids and immunosuppressives. However, mounting evidences manifested that top-down therapy with early administration of anti-TNF or combination of immunosuppressives can achieve more rapid and higher rate of mucosal healing and has the potential of modifying the natural course of disease. Therefore, who is suitable to accept and when to start anti-TNF therapy have attracted the attention of gastroenterologists. And what benefit/risk can be expected from the two strategies should be carefully taken into account by clinicians. Age stratification, special patients, disease location and extension, genetic and serologic testing are predictors of disease progression and complication and thus guide a personalized treatment approach in CD. A definition of early CD has been proposed to select an algorithm for treatment of moderate-to-severe CD with a suitable strategy. To date mucosal healing has been widely used, the Lémann score, which assesses the extent and severity of bowel damage at a specific time-point and over time, and is a new disability index for patients with CD, will be considered as a new endpoint for future studies of treatment strategies. Besides medicines of the two strategies, surgery, vaccine, Leukocytapheresis and stem cell therapy are all effective therapeutic approaches which lead to another thinking about what should they be putted in the conditional pyramid. However, we are trying to answer these questions.

摘要

克罗恩病(CD)是一种慢性免疫介导性疾病,病程呈进行性和破坏性。当前的治疗策略指南仍推荐采用逐步升级的方法,依次使用皮质类固醇和免疫抑制剂。然而,越来越多的证据表明,早期给予抗TNF或联合使用免疫抑制剂的自上而下疗法能够实现更快且更高比例的黏膜愈合,并有改变疾病自然病程的潜力。因此,谁适合接受以及何时开始抗TNF治疗已引起胃肠病学家的关注。临床医生应仔细考虑这两种策略可能带来的益处/风险。年龄分层、特殊患者、疾病部位和范围、基因及血清学检测是疾病进展和并发症的预测因素,从而指导CD的个性化治疗方法。已提出早期CD的定义,以选择一种适合的策略来治疗中重度CD的算法。迄今为止,黏膜愈合已被广泛应用,Lémann评分可在特定时间点及随时间评估肠道损伤的程度和严重程度,是CD患者的一种新的残疾指数,将被视为未来治疗策略研究的新终点。除了这两种策略的药物外,手术、疫苗、白细胞去除术和干细胞疗法都是有效的治疗方法,这引发了对它们应如何置于条件金字塔中的另一种思考。然而,我们正在努力回答这些问题。